HeartSciences Inc. (NASDAQ:HSCS) Sees Significant Increase in Short Interest

HeartSciences Inc. (NASDAQ:HSCS) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 75,969 shares, a growth of 160.9% from the December 15th total of 29,118 shares. Currently, 2.4% of the company’s shares are sold short. Based on an average daily trading volume, of 73,534 shares, the days-to-cover ratio is presently 1.0 days. Based on an average daily trading volume, of 73,534 shares, the days-to-cover ratio is presently 1.0 days. Currently, 2.4% of the company’s shares are sold short.

HeartSciences Trading Down 4.4%

Shares of NASDAQ:HSCS opened at $3.03 on Wednesday. The company has a market capitalization of $9.63 million, a PE ratio of -0.44 and a beta of 2.52. HeartSciences has a 12-month low of $2.01 and a 12-month high of $6.47. The business’s fifty day simple moving average is $2.78 and its 200-day simple moving average is $3.29.

HeartSciences (NASDAQ:HSCS) last released its quarterly earnings results on Monday, December 15th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.05. The firm had revenue of $2.42 million during the quarter, compared to the consensus estimate of $0.00 million. Research analysts predict that HeartSciences will post -10.01 EPS for the current year.

Institutional Trading of HeartSciences

A hedge fund recently bought a new stake in HeartSciences stock. Geode Capital Management LLC bought a new position in shares of HeartSciences Inc. (NASDAQ:HSCS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.51% of HeartSciences as of its most recent SEC filing. Hedge funds and other institutional investors own 17.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HSCS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, December 29th. Wall Street Zen upgraded HeartSciences from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd. Finally, Ascendiant Capital Markets upped their price objective on shares of HeartSciences from $9.00 to $9.20 and gave the stock a “buy” rating in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.20.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.